StreetInsider.com News Articles

Oral Wegovy reaches 33% of total prescriptions by May

Thu, 18 Jun 2026 05:47:49 -0400

Investing.com -- Oral Wegovy accounted for approximately 33% of total Wegovy prescriptions in May, according to a Bank of America report released Thursday. The oral formulation reached 159,000 weekly total prescriptions in the week ending June 5, 2026.

The oral version of Wegovy launched in early January and has grown rapidly since its introduction. Weekly new prescriptions for oral Wegovy represented 40% of total new Wegovy prescriptions in the week ending June 5, 2026. The mix of oral prescriptions has stabilized in the low-30% range over recent weeks after initial rapid growth.

The broader GLP-1 drug category showed weekly total prescription growth

Oral Wegovy reaches 33% of total prescriptions by May

Thu, 18 Jun 2026 05:47:49 -0400

The broader GLP-1 drug category showed weekly total prescription growth

Oral Wegovy reaches 33% of total prescriptions by May

Thu, 18 Jun 2026 05:47:49 -0400

The broader GLP-1 drug category showed weekly total prescription growth

Oral Wegovy reaches 33% of total prescriptions by May

Thu, 18 Jun 2026 05:47:49 -0400

The broader GLP-1 drug category showed weekly total prescription growth

Oral Wegovy reaches 33% of total prescriptions by May

Thu, 18 Jun 2026 05:47:49 -0400

The broader GLP-1 drug category showed weekly total prescription growth

Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says

Wed, 17 Jun 2026 11:15:05 -0400

Investing.com -- Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.

Duato made the comments during an interview with Carlyle Group cofounder David Rubenstein at the Economic Club of Washington, DC. The decision separates J&J from competitors working to develop or buy obesity treatments after successful weight-loss drugs from Eli Lilly and Novo Nordisk.

"We are not going to be in the GLP-1 area," Duato said. He pointed to oncology and neuroscience as areas where the company can make a larger impact.

The New Brunswick,

Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says

Wed, 17 Jun 2026 11:15:05 -0400

Investing.com -- Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.

"We are not going to be in the GLP-1 area," Duato said. He pointed to oncology and neuroscience as areas where the company can make a larger impact.

The New Brunswick,

Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says

Wed, 17 Jun 2026 11:15:05 -0400

Investing.com -- Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.

"We are not going to be in the GLP-1 area," Duato said. He pointed to oncology and neuroscience as areas where the company can make a larger impact.

The New Brunswick,

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK325 at Berenberg

Wed, 17 Jun 2026 04:27:03 -0400

Berenberg analyst Kerry Holford raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK325.00 (from DKK300.00) while maintaining a Buy rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK325 at Berenberg

Wed, 17 Jun 2026 04:27:03 -0400

Berenberg analyst Kerry Holford raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK325.00 (from DKK300.00) while maintaining a Buy rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK325 at Berenberg

Wed, 17 Jun 2026 04:27:03 -0400

Berenberg analyst Kerry Holford raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK325.00 (from DKK300.00) while maintaining a Buy rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK325 at Berenberg

Wed, 17 Jun 2026 04:27:03 -0400

Berenberg analyst Kerry Holford raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK325.00 (from DKK300.00) while maintaining a Buy rating.

Novo Nordisk to seek approval soon to sell Wegovy pill in China

Tue, 16 Jun 2026 02:02:18 -0400

By Andrew Silver

BEIJING, June 16 (Reuters) - ‌Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight-loss pill "very soon," its CEO said on Tuesday, as it moves to catch up with rival ‌Eli Lilly in the world's second-largest pharmaceutical market.

Denmark's Novo and U.S.-based ⁠Lilly believe weight-loss pills could attract patients reluctant to use injections and

Novo Nordisk to seek approval soon to sell Wegovy pill in China

Tue, 16 Jun 2026 02:02:18 -0400

By Andrew Silver

Denmark's Novo and U.S.-based ⁠Lilly believe weight-loss pills could attract patients reluctant to use injections and

Form 6-K NOVO NORDISK A S For: Jun 15

Mon, 15 Jun 2026 07:43:00 -0400

si-local-file:///var/storage/secattach/20260615/26644278.html

Form 6-K NOVO NORDISK A S For: Jun 15

Mon, 15 Jun 2026 07:43:00 -0400

si-local-file:///var/storage/secattach/20260615/26644278.html

Form 6-K NOVO NORDISK A S For: Jun 15

Mon, 15 Jun 2026 07:43:00 -0400

si-local-file:///var/storage/secattach/20260615/26644278.html

Leerink highlights drug demand rebound after Memorial Day